Cognito Therapeutics Announces Presentations for Novel Therapeutic in Alzheimer’s Disease at the 2022 American Academy of Neurology (AAN) Conference
“We’ve identified a potential biomarker to predictively identify patients more likely to benefit from our gamma stimulation-based therapeutic intervention in Alzheimer’s Disease, and we’re excited to debut our findings for the first time at AAN,” said Brent Vaughan, CEO, Cognito Therapeutics. “In our clinical study, specific neurophysiological responses to gamma sensory stimulation were shown to be predictive of positive clinical outcomes including significant improvement in cognitive and functional abilities, as well as decreased brain atrophy in Alzheimer’s patients. These findings could have important implications for patient selection in clinical studies with our therapy.”
The presentations are as follows:
Poster Title: Coherent Activity in EEG Response to Gamma Sensory Stimulation Predicts Positive Outcome in Cognitive and Functional Abilities, and Brain Atrophy in Subjects with Alzheimer’s Disease
Authors: Dr. Aylin Cimenser, et al.
Date/Time: Sunday, April 3 from 8:00 AM - 9:00 AM PT
Oral Presentation Title: Feasibility, Safety, and Efficacy of Gamma Sensory Stimulation as a Novel Therapeutic Intervention for Alzheimer’s Disease
Authors: Dr. Tom Megerian, Dr. Mihaly Hajos, et al.
Session: N1 - Neuroscience in the Clinic: Neurobiology of Learning and Memory in 2022
Date/Time: Saturday, April 2 at 12:50 PM PT
Neuroscience in the Clinic Sessions are designed to bring cutting-edge scientific research together with clinical application. The two-hour sessions will feature case presentations, invited discussants, and abstract presentations. The session will conclude with a panel discussion that will include the invited discussants, as well as the abstract presenters.
For more information about the abstracts, please visit www.aan.com/events/annual-meeting.
About Cognito Therapeutics
Cognito Therapeutics is a pioneer in disease-modifying therapeutic interventions for neurodegenerative diseases and human cognitive performance. The company has completed multiple clinical studies demonstrating its investigational therapeutic platform has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimer’s disease. Cognito has received FDA Breakthrough Device Designation treatment of the cognitive and functional symptoms associated with Alzheimer's disease in individuals diagnosed with mild to moderate Alzheimer’s and expects to start pivotal studies in 2022. The company’s technology was based on pioneering optogenetics research by scientific co-founders Professors Li-Huei Tsai and optogenetics pioneer Ed Boyden at MIT. Cognito Therapeutics is based in Cambridge, MA. For more information, please visit www.cognitotx.com. Follow us on Twitter at @cognitotx.
Source: Cognito Therapeutics